Is Appili Therapeutics Inc (APLIF) a Buy, Sell, or Hold?
OTC : APLIF
Appili Therapeutics Inc — News
$0.0078 USD
$0.0 (-2.5%)
- Volume
- 80K
- Average Volume
- 36.06K
- Market Capitalization
- $1.03M
- P/E Ratio
- -0.30
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $0.03
- Year Low
- $0.01
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.11
| Source | Headline |
|---|---|
|
Appili Therapeutics Announces Receipt from NIAID of a Notice of Termination for Convenience on the Contract for the VXV-01 Program
HALIFAX, Nova Scotia, July 03, 2026 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases today announced that it has received a Notice of Termination for Convenience from the National Institute of Allergy and Infectious Diseases (“NIAID”), part of the National Institutes of Health (“NIH”), in connection with the Company's contract supporting development of the VXV-01 fungal vaccine candidate. globenewswire.com - 2026-07-03 18:10:00 |
|
Appili Therapeutics Reports Fiscal Year 2026 Financial and Operational Results
LIKMEZ® (ATI-1501) commercial momentum building in U.S. market US$40 million NIAID award supporting VXV-01 advancement through Phase 1 globenewswire.com - 2026-06-26 18:29:00 |
